

## Medicaid Policy Routing and Tracking Form

Date: 8/31/2016

Assignment Title: Puberty Suppression

Assignment Type: GAPMS

Final Due Date:

Assignment Summary (brief): GAPMS on Hormone Suppression

Attachment(s): Puberty Suppression -GAPMS Report Stu.edits.docx  
WorksCited8.30.16.docx

Section: Medical and Behavioral Health Coverage Policy

Prepared By: Monique Johnson

Position: Program Administrator

Preparer Phone: 4-4212

Preparer Room Number: 2324

**Reviewed by and Routing Timeline(s):**

Name	Title	Start Date	End Date	Date Received	Today's Date and Initial	Approval
Erica Floyd-Thomas	AHC Administrator	8/30/2016	8/30/2016	8/30/2016	8/30/2016 EFT	<input checked="" type="checkbox"/>
Shevaun Harris	Bureau Chief	8/30/2016	9/8/2016	8/30/2016	9/8/2016 SH	<input checked="" type="checkbox"/>
Beth Kidder	ADS Policy/Quality	9/8/2016	9/13/2016	9/8/2016	9/13/2016 BK	<input checked="" type="checkbox"/>
Justin Senior	Medicaid Director			9/13/2016	9/15/2016 Bk ...	<input checked="" type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Notes: SH edits completed 8/31/16. MJ  
BK edits completed 9/13/16. MJ





Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	September 13, 2016

## **PUBERTAL SUPPRESSION WITH GONADOTROPIN-RELEASING HORMONE ANALOG AGENT FOR GENDER DYSPHORIA**

**LENGTH OF AUTHORIZATION: THREE MONTHS**

### **CLINICAL CRITERIA:**

Gender dysphoria is defined as distress or discomfort caused by a discrepancy between a person's assigned sex at birth and a person's gender identity. Unresolved, the distress or discomfort can manifest into a host of behavioral health problems including depression, anxiety, suicidal ideation and self-mutilation. The purpose of pubertal suppression is to alleviate suffering caused by the development of secondary sex characteristics, to provide time to make a balanced decision regarding the actual gender reassignment.<sup>1</sup>

### **REVIEW CRITERIA:**

- Comprehensive mental health evaluation required including the diagnosis of gender dysphoria, using the current Diagnostic and Statistical Manual of Mental Disorders-5 by a licensed qualified mental health provider (MHP) with experience in treating patients with gender dysphoria (supporting documentation required).<sup>2</sup>
- The diagnosis must be confirmed by an endocrinologist.<sup>2</sup>
- MHP clinical notes must conclude that not treating the patient is likely to be worse than the potential long-term consequences of the treatment. The treatment must be medically necessary (e.g. it is administered to protect life and/or prevent significant disability, such as to prevent suicide or self-mutilation), and must ensure that the pubertal suppression treatment approach presents as the best alternative given the patient's psychological state and presenting signs and symptoms (supporting documentation required).
- Patient must have been in psychotherapy for a minimum of six months since diagnosed with gender dysphoria prior to consideration for pubertal suppression therapy.
- Females and males must reach at least a Tanner stage 2 or Tanner stage 3 prior to consideration of pubertal suppression therapy and have confirmed pubertal levels of estradiol and testosterone, respectively.<sup>2</sup> If treatment is being prescribed for adolescents under the age of 12, additional documentation is required to support the request.
- MHP clinical notes must address the patient's readiness for pubertal suppression treatment and ensure psychotherapy will continue to be offered while on pubertal suppression therapy.<sup>3</sup>
- Parental consent is required during treatment for patients under the age of 18.<sup>4</sup> The patient and the legal guardian/parents must demonstrate knowledge and understanding of the expected



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	September 13, 2016

outcomes of suppression of pubertal hormones including the reversible and irreversible effects of pubertal suppression therapy (supporting documentation required).<sup>2</sup>

- Evidence that other psychiatric or medical comorbidities that may interfere with the diagnostic work-up or treatment have been ruled out.<sup>3</sup>
- Documentation of treatment adherence is required.

<sup>1</sup>The Standards of Care for Gender Identity Disorders (5<sup>th</sup> Ed) Harry Benjamin International Gender Dysphoria Association, Inc. Available at: <http://www.tc.umn.edu/~colem001/hbigda/hstndrd.htm> Accessed September 9, 2016

<sup>2</sup>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:3132-3154

<sup>3</sup>Vance SR, Ehrensaft D, Rosenthal SM, et al. Psychological and Medical Care of Gender Nonconforming Youth Pediatrics 2014; 134:1184-1192

<sup>4</sup>Cavanaugh T Cross-Sex Hormone Therapy. Available at: <http://www.lgbthealtheducation.org/wp-content/uploads/Cross-Sex-Hormone-Therapy1.pdf> Accessed September 9, 2016



RICK SCOTT  
GOVERNOR

ELIZABETH DUDEK  
SECRETARY

**PUBERTY SUPPRESSION THERAPY  
GENERALLY ACCEPTED PROFESSIONAL MEDICAL STANDARDS (GAPMS)  
DETERMINATION REPORT WITH RECOMMENDATION**

**Date:** April 11, 2022  
**To:** Justin Senior, Deputy Secretary for Medicaid  
**From:** Bureau of Medicaid Policy  
**Subject:** Puberty Suppression Therapy

---

**PURPOSE**

In order for the use of puberty suppression therapy to be covered under the Florida Medicaid program, it must meet medical necessity criteria as defined in Rule 59G-1.010, Florida Administrative Code (F.A.C.), and be funded through the General Appropriations Act of Chapter 216, Florida Statutes (F.S.).

Pursuant to the criteria set forth in Rule 59G-1.010, F.A.C., the use of puberty suppression therapy must be consistent with generally accepted professional medical standards (GAPMS) as determined by the Medicaid program, and not experimental or investigational.

In accordance with the determination process established in Rule 59G-1.035, F.A.C., the Deputy Secretary for Medicaid will make the final determination as to whether the use of puberty suppression therapy is consistent with generally accepted professional medical standards and not experimental or investigational.

If it is determined that puberty suppression therapy is consistent with generally accepted professional medical standards, this report will be supplemented with an addendum which analyzes additional factors to determine whether this health service should be covered under the Florida Medicaid program.

**REPORT WITH RECOMMENDATION**

This report with recommendation is presented as the summary assessment considering the factors identified in Rule 59G-1.035, F.A.C., based on the collection of information from credible sources of reliable evidence-based information. The intent is to provide a brief analysis with justification in support of the final recommendation.

The analysis described in this report includes:

- A high level review of relevant disease processes.
- An overview of the health service information.
- Clearance from the government regulatory body (e.g., Food and Drug Administration).

2727 Mahan Drive • Mail Stop # 20  
Tallahassee, FL 32308  
AHCA.MyFlorida.com



Facebook.com/AHCAFlorida  
Youtube.com/AHCAFlorida  
Twitter.com/AHCA\_FL  
SlideShare.net/AHCAFlorida

- Evidence based clinical practice guidelines.
- A review of the literature considered by the relevant medical community or practitioner specialty associations from credible scientific evidence-based literature published in peer reviewed journals and consensus of coverage policy from commercial and other state Medicaid insurers.

## **HEALTH SERVICE SUMMARY**

### **Hormones**

Hormones are important chemical messengers in the body that effectively transfer signals and instructions from one set of cells to another. Hormones are secreted into the bloodstream by a collection of glands inside the body referred to as the endocrine system. A gland is a group of cells that produces and secretes chemicals into the body. The major glands that make up the endocrine system include the hypothalamus, pituitary gland, thyroid and parathyroid, adrenals, pineal body, and the ovaries and testes.

In a laboratory setting, hormones are produced synthetically and are prescribed by physicians to treat disease or hormone deficiencies. An instance where synthetic hormones may be needed is when an individual has their thyroid gland surgically removed; a practitioner may prescribe synthetic thyroid hormones to replace those that their body can no longer produce.

Over 50 different hormones have been identified in the human body, and more are still being discovered. Hormones influence and regulate practically every cell, tissue, organ, and function of the body, including growth, development, metabolism, homeostasis, and sexual and reproductive function.<sup>20</sup>

### **Reproductive Hormones**

The hormones commonly considered as reproductive hormones in the body are testosterone, estrogen, and progesterone. Testosterone is often referred to as a male hormone, and estrogen and progesterone are often referred to as female hormones. However, there are no exclusively male or female hormones that have been identified. The physical manifestations of gender result from differences in the amounts of individual hormones in the body and differences in their patterns of secretion, first in utero and then again during puberty. In other words, testosterone, estrogen, and progesterone are produced by men and women, but in differing amounts and in different patterns.<sup>20</sup>

### **Reproductive Hormone Suppression Therapy**

There are many disease processes in which increased levels of reproductive hormones are released. They include, but are not limited to, prostate cancer, breast cancer, severe endometriosis, and central precocious puberty. To address the over-secretion of reproductive hormones, several drugs have been developed to aid in reducing hormone levels, including those hormones released during puberty.

For the purposes of this report, an analysis is being performed on the use of hormone treatment to suppress puberty. Currently, there are a number of drugs used to suppress puberty, which all use gonadotropin-releasing hormone (GnRH) agonists. Agonists function to stop receptors from connecting with the appropriate transmitter. For a hormone to perform its primary function in the

brain and body it must find the correct receptor to transmit its response; the GnRH agonists prevent this natural cycle.<sup>20</sup>

### Government Regulatory Body Approval

The Food and Drug Administration (FDA) has approved three drugs for the use in children for the purpose of puberty suppression therapy, as follows:

- Lupron<sup>44</sup>
  - Indications for use: Palliative treatment of advanced prostatic cancer and central precocious puberty in children of both sexes.
- Synarel<sup>47</sup>
  - Indications for use: Central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes and endometriosis.
- Supprelin<sup>46</sup>
  - Indications for use: Central precocious puberty in both sexes.

Each of these drugs has specific indications for use and dosing information. Additionally, these medications have approved off-label uses. This permits usage in other than the approved FDA indications. These approved off-label uses are compiled in three compendia: American Hospital Formulary Service Drug Information (AHFS), United States Pharmacopeia-Drug Information (or its successor publications), and DRUGDEX Information System.<sup>7</sup> The drugs specified above are authorized in the respective compendia to treat the following conditions:

- Lupron:
  - Breast cancer
  - In vitro fertilization
  - Ovarian cancer
  - Premenstrual syndrome
  - Prostate cancer
  - Prostate cancer, Neoadjuvant treatment
  - Uterine leiomyoma
- Synarel:
  - Benign prostatic hyperplasia
  - Contraception, Female; prophylaxis
  - Contraception, Male; prophylaxis
  - Crohn's disease
  - Hirsutism
  - In vitro fertilization
  - Uterine leiomyoma
- Supprelin:
  - Acute intermittent porphyria
  - Endometriosis
  - Female infertility; Adjunct
  - Polycystic ovary syndrome
  - Uterine leiomyoma

While all of these drugs may be utilized to treat other conditions, as indicated above and specified in the compendia, none of them are authorized or specified in the compendia for use in treating individuals diagnosed with gender dysphoria.<sup>7</sup>

## LITERATURE REVIEW

This analysis summarizes information obtained from scientific literature published in credible peer-reviewed journals related to the use of puberty suppression therapy. This section also briefly cites the positions from the relevant medical societies, and summarizes the key articles referenced in support of their positions.

### Central Precocious Puberty

Central precocious puberty (CPP) develops due to premature pubertal changes and rapid bone development. CPP is associated with lower adult height and increased risk for development of psychological problems.

Reproductive hormone suppression therapy (also referred to as puberty suppression therapy in this document) has been the standard of care for CPP for the last 15-20 years. The standard treatment for CPP is GnRH analogs. Although there are many different analogs with different routes of administration, the primary agent in the United States for many years was depot intramuscular injections administered every four weeks, but in the last ten years, a subdermal or under the skin implant has been developed, which has been shown to be effective for up to two years.<sup>17, 39, 41</sup>

In a recent study, researchers explored the difference in cognitive function, behavior, emotional reactivity, and psychosocial problems between young females treated with GnRH and age-matched controls. They concluded that young females treated with GnRH do not differ in their cognitive functioning, behavioral, and social problems from their same age peers. However, they did find a significant difference in heart rate that increased with treatment duration and suggested a follow-up study with an emphasis on cardiac health.<sup>55</sup>

### Gender Dysphoria

Gender dysphoria is an individual's affective or cognitive discontent with their assigned gender (gender at birth).<sup>14</sup> Gender dysphoria refers to the distress that may accompany the incongruence between the individual's experienced or expressed gender and their assigned gender. Evidence of this distress is the hallmark of the disorder. The diagnostic criteria are divided into a category for children and a category for adolescents and adults. The disorder is manifested differently as an individual ages or enters different developmental stages. Both categories require marked incongruence between the individual's experienced or expressed gender and their assigned gender of at least a six months' duration and clinically significant distress or impairment in social, school (occupation for adults), or other important areas of functioning.<sup>14</sup>

Diagnostic criteria in children include: a strong desire to be the other gender or an insistence that they are the other gender; a preference for wearing clothing associated with the other gender; preference for cross gender roles in simulated play; preference for toys games, or activities usually associated with the other gender; preference for playmates of the other gender; and the dislike of their sexual anatomy. The prevalence of this diagnosis among the general population ranges from 0.005% to 0.014% in males and 0.002% to 0.003% in females.<sup>14</sup>



Studies have shown that the majority of children (80%) diagnosed with gender dysphoria will not continue to be gender dysphoric after puberty.<sup>31</sup>

In adolescents and adults, diagnostic criteria include: a strong desire to be and to be treated as the other gender and a strong desire to have the sex characteristics of the other gender (or in the case of adolescents, the wish to prevent the development of their assigned gender's characteristics).<sup>14</sup>

Gender dysphoria is associated with high levels of stigmatization, discrimination, and victimization, leading to negative self-concept, increased rates of mental disorder comorbidity, school dropout, and economic marginalization.<sup>14</sup> Adolescents that do not receive treatment during this already vulnerable period of development might engage in risky or self-harming behaviors, such as self-harm, self-mutilation, suicidal ideation, or suicide.<sup>22</sup>

For the 20% of children who persist in their feelings of gender dysphoria, clinicians may begin to explore alternative treatment approaches beyond psychotherapy after the onset of puberty, including medical interventions such as the use of GnRH analogs to suppress puberty.<sup>38</sup> The use of puberty suppression therapy is used as a diagnostic aid in adolescents contending with gender dysphoria.<sup>6, 10, 11, 24, 31, 50</sup> The use of GnRH analogs is generally prescribed in adolescents ages 12-16. In addition to puberty suppression therapy, a physician may also begin to prescribe cross-sex hormones, though the latter does not generally begin until the ages of 16-18.<sup>10, 11</sup>

The use of GnRH analogs will delay reproductive development in this population. However, there remains a great deal of concern and lack of consensus in the medical community of the potential risks, including: misdiagnosis, sterilization, adverse medical effect on the metabolic and endocrine system, impaired bone mass and brain development, etc.<sup>51, 6</sup> To date, there have been no randomized controlled clinical trials on the use of GnRH analogs in the treatment of gender dysphoria (on large cohorts) that have been shown to be efficacious with tolerable side effects. This is in large part due to the small number of patients diagnosed with gender dysphoria, which makes any statement on the general efficacy of a treatment approach challenging.<sup>31</sup> However, there have been case-studies (qualitative) that have been conducted that review the outcomes on small cohorts. These studies have concluded that there are limited negative side effects from the use of puberty suppression drugs in adolescents contending with gender dysphoria.<sup>54, 55</sup>

Clinicians who support the use of puberty suppression therapy in the treatment of gender dysphoria argue that the risks of misdiagnosis are significantly reduced if the treatment is delayed until the initiation of puberty. They also contend that this treatment may relieve emotional distress in the individual (including reducing suicidal ideation in severe cases) and may "buy time" for the child to explore their feelings of gender dysphoria without contending with physical changes that cannot be undone (e.g., breast development).<sup>22</sup> Most treatment protocols recommend extensive psychological evaluations/assessments and psychotherapy by mental health professionals prior to the initiation of medical interventions. This is especially important given the changing thoughts and feelings of prepubescent children versus adolescents with persistent gender dysphoria and in adolescents presenting with co-morbid conditions.

It is important to note that most of the literature reviewed in development of this analysis concluded that more systematic research is required to determine the long-term efficacy of medical treatment for adolescents with gender dysphoria.<sup>21, 24, 25, 28, 50, 51</sup>

## Evidence-Based Clinical Practice Guidelines

The American Academy of Pediatrics published a consensus statement on the use of GnRH analogs in children in March 2009. They concluded that GnRH use was undisputed in the treatment of CPP early-onset (less than six years old). However, the use of GnRH for conditions other than CPP requires additional investigation and cannot be suggested routinely.<sup>3</sup> The consensus statement does not specifically address the use of GnRH in the treatment of gender dysphoria.

The Endocrine Society published guidelines for the endocrine treatment of transsexual persons. The Society concluded that transsexual persons seeking to develop the physical characteristics of the desired gender require safe, effective hormone regimen that will 1) suppress endogenous hormone secretion determined by the person's genetic/biological sex and 2) maintain sex hormone levels within the normal range for the person's desired gender. They recommend that a mental health professional make the referral and participate in ongoing care and an endocrinologist must confirm the diagnostic criteria. They do not recommend endocrine treatment of prepubertal children. The recommendations are as follows:

- Treatment of transsexual adolescents (Tanner stage two, generally achieved around the age of 12 years) by suppressing puberty with GnRH analogues until the age of 16 years.
- Initiation of cross-sex hormones at the age of 16 years with continued suppression of biological sex hormones.
- Maintaining physiologic levels of gender-appropriate sex hormones and monitoring for known risks throughout adulthood.<sup>19, 18, 32</sup>

In making these recommendations, however, the Endocrine Society identified the strength of the evidence used to support its conclusions. For all of the recommendations listed above, the Society acknowledged the strength of the evidence as low or very low.

## COVERAGE POLICY

### Federal Regulations

Federal regulations for Medicaid specify that a state may limit coverage of a drug with respect to the treatment of a specific disease or condition for an identified population (if any) based on the drug's labeling, if it does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome of such treatment for such population over other drugs included in the formulary. In addition, states may exclude a drug when the prescribed use of the drug is not for a medically accepted indication, either approved by the FDA or supported by information from the appropriate compendia. These guidelines apply to a state's administration of its Medicaid prescribed drug benefit in both managed care and non-managed care delivery systems.

States are also required to implement a drug use review program for covered outpatient drugs in order to assure that prescriptions are appropriate, medically necessary, and are not likely to result in adverse medical results. The program is required to assess data on drug use against predetermined standards, consistent with the following:

1. Compendia, consisting of the following:
  - a. American Hospital Formulary Service Drug Information;
  - b. United States Pharmacopeia-Drug Information (or its successor publications); and
  - c. the DRUGDEX Information System; and
2. The peer-reviewed medical literature.

Federal law requires states to provide services to eligible recipients under the age of 21 years, if such services are medically necessary to correct or ameliorate a defect, a condition, or a physical or mental illness. This is known as the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit. Included are diagnostic services, treatment, equipment, supplies, and other measures described in section 1905(a) of the Social Security Act, codified in Title 42 of the United States Code 1396d (a). As such, services for recipients under the age of 21 years exceeding any coverage limitations specified within a state's policies maybe approved, if medically necessary.

### **Florida Medicaid**

In order to be reimbursed by Florida Medicaid, a drug must be medically necessary and either (a) prescribed for medically accepted indications and dosages found in the drug labeling or drug compendia in accordance with section 1927(k) (6) of the Social Security Act, or (b) prior authorized by a qualified clinical specialist approved by the Agency for Health Care Administration (Agency).<sup>1</sup>

The criteria that are utilized under the Florida Medicaid program in the authorization of drugs for off-label purposes are as follows:

1. Documentation submitted with trial and failure or intolerance to all FDA- approved medications for the indication **AND**
2. Phase III clinical studies published in peer review journals to support the non-FDA approved use **AND**
3. Usage supported by publications in peer reviewed medical literature **and** one or more citations in at least one of the following compendia:
  - a. American Hospital Formulary Service Drug Information (AHFS)
  - b. United States Pharmacopeia-Drug Information (or its successor publications)
  - c. DRUGDEX Information System<sup>1</sup>

Florida Medicaid covers reproductive hormone suppression therapy (including puberty suppression therapy) for all FDA approved indications/uses or when the information in the appropriate compendium supports the use of the drug in the treatment of the specific disease state or condition. Since the use of GnRH agonists are not FDA approved or listed in the appropriate compendia for the treatment of gender dysphoria, Florida Medicaid does not authorize these drugs for such uses. However, children/adolescents diagnosed with gender dysphoria are eligible to receive an array of other medical and behavioral health interventions (e.g., individual and family therapy, psychological evaluations/assessments, other medical evaluation and management services) necessary to address their presenting signs and symptoms.

Health plans contracted to provide services under the Florida Medicaid Statewide Medicaid Managed Care program are required to cover all prescription drugs listed in the Agency's Medicaid Preferred Drug List (PDL). In addition, the health plan's prior authorization criteria and protocols may not be more restrictive than those used by the Agency as indicated in the Florida Statutes, the Florida Administrative Code, the Medicaid State Plan and those posted on the Agency website.

Florida Medicaid provides services to eligible recipients under the age of 21 years, if such services are medically necessary to correct or ameliorate a defect, a condition, or a physical or mental illness. Medical necessity in the State of Florida must meet the following conditions:

1. Be necessary to protect life, to prevent significant illness or significant disability, or to alleviate severe pain;
2. Be individualized, specific, and consistent with symptoms or confirmed diagnosis of the illness or injury under treatment, and not in excess of the patient's needs;
3. Be consistent with generally accepted professional medical standards as determined by the Medicaid program, and not experimental or investigational;
4. Be reflective of the level of service that can be safely furnished, and for which no equally effective and more conservative or less costly treatment is available statewide; and
5. Be furnished in a manner not primarily intended for the convenience of the recipient, the recipient's caretaker, or the provider.

If a service exceeds the coverage described within a Florida Medicaid policy or the associated fee schedule, a request (along with all supporting documentation) may be submitted to the Agency or its designee for review.

### **Medicare**

Medicare covers reproductive hormone suppression for all FDA approved use. The *Medicare Benefit Policy Manual*, Chapter 15, page 15, subsection 50.4.2, discusses the unlabeled use of a drug. The policy states that "FDA approved drugs used for indications other than what is indicated on the official label may be covered under Medicare if the carrier determines the use to be medically accepted, taking into consideration the major drug compendia, authoritative medical literature and/or accepted standards of medical practice."<sup>5</sup> However, because Medicare covers primarily elderly adults and disabled adults, its coverage policies have little or no application in this analysis.

### **State Medicaid Programs**

All state Medicaid programs cover reproductive hormone suppression therapy for the approved FDA indications and when the criteria for off-label use are met. Some state Medicaid programs are also adopting coverage policies that allow for reimbursements of puberty suppression therapy in adolescents diagnosed with gender dysphoria. It appears at this time as though most states do not cover this service although that may change over time. This report highlights the coverage policies for four Medicaid programs that do cover the service, as follows:

1. Colorado Medicaid covers behavioral health services, GnRH analogs/agonists, cross-sex hormone therapy, gender confirmation surgery, and pre and post-operative care.
2. Maryland Medicaid covers GnRH treatment if the recipient has a diagnosis of gender dysphoria.
3. Rhode Island Medicaid covers behavioral health services, pharmacological and hormonal therapy to delay physical changes of puberty, and pharmacological and hormonal therapy that is non-reversible and produces masculinization or feminization. Some services require prior authorization.
4. Washington State Medicaid covers behavioral health services, puberty suppression therapy, hormonal therapy, and gender reassignment surgery.

**GENERALLY ACCEPTED PROFESSIONAL MEDICAL STANDARDS RECOMMENDATION**

Puberty suppression therapy is considered a health service that is consistent with generally accepted professional medical standards for the approved FDA indications (i.e., central precocious puberty) and for off-label use when supported by citations in at least one of the compendia. Since Florida Medicaid already provides coverage of puberty suppression therapy in the treatment of central precocious puberty and for use in treating the conditions cited in the compendia, no further policy coverage analyses are needed to supplement this report on this point.

Based upon the available published literature, it is inconclusive whether puberty suppression therapy is considered a health service that is consistent with generally accepted professional medical standards in the treatment of gender dysphoria. Most of the studies published thus far on the use of puberty suppression in gender dysphoric children/adolescents have concluded that further systematic research is required to determine the long-term safety and efficacy of this approach and there remains a lack of consensus within the medical community on its appropriateness (both from an ethical and safety perspective). As the research on this topic continues to evolve, more conclusive evidence may emerge that supports the long-term efficacy and effectiveness of this treatment approach. At any time, a follow-up analysis can be performed that could change this recommendation.

**EPSDT Considerations:**

While the Agency cannot make a blanket determination on puberty suppression therapy for gender dysphoria, we also cannot categorically exclude this treatment for children. Clinical guidelines from the Endocrine Society do recommend this therapy for certain adolescents, albeit based upon a combination of weak and very weak evidence. In certain circumstances, the risks of not treating an adolescent may be worse than the potential long-term consequences of treatment. Moreover, it is noted extensively in the literature that adolescents contending with gender dysphoria often experience a myriad of emotional, physical, and societal challenges. Unresolved, the distress can manifest into a host of behavioral health problems including depression, anxiety, and suicidal ideation and self-mutilation. Florida pays for services for children when they protect life and /or prevent significant disability or harm, in accordance with the state's medical necessity definition.

Given these concerns, while it is not recommended that any further analyses be conducted to expand Florida Medicaid's coverage of puberty suppression therapy beyond those indications/uses approved by the FDA or authorized in the appropriate compendium, it is recommended that any individualized request for such therapy be reviewed as a part of the Agency's special services process. Consistent with EPSDT requirements, the request can be evaluated on an individualized basis to determine if the service is medically necessary (e.g. it is administered to protect life and/or prevent significant disability, such as to prevent suicide or self-mutilation) to ensure that all less invasive interventions have been exhausted, and to ensure that this treatment approach presents as the best alternative given the adolescent's psychological state and presenting signs and symptoms.

**Concur**

**Do not Concur**

**Comments:**

---

---

Deputy Secretary for Medicaid (or designee)

Date

Works Cited

1. Agency for Healthcare Administration: Off Label Use Criteria
2. Anderson, S. (August 2015). Disorders of Sexual Differentiation: Ethical Considerations Surrounding Early Cosmetic Genital Surgery. *Pediatric Nursing*, v. 41.
3. Carel, J., Eugster, E., Rogol, A., Ghizzoni, L., & Palmert, M. R. (March 2009). Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children. *The American Academy of Pediatrics*, 2009, 555-556. doi:10.1016/s0084-3873(09)79462-3.
4. Centers for Medicaid and Medicare. (June 2016). Proposed Decision Memo for Gender Dysphoria and Gender Reassignment Surgery (CAG-00446N).
5. Centers for Medicaid and Medicare. (March 2016). Medicare Benefit Policy Manual: Chapter 15- Covered Medical and Other Health Services, subsection 50.4.2, Unlabeled Use of Drug.
6. Cohen-Kettenis, P.T., Schagen, S.E.E., Steensma, T.D. et al. (2011). Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up. *Archives of Sexual Behavior*. 40(4), 843 - 847.
7. Compendia: MicroMex Solutions. (Truven Health Analytics) Lupron, Supprelin, Synarel, and Vantas
8. Cruz v. Zimmerman, 116 F. Supp. 3d 334 (S.D.N.Y. 2015)
9. Daly, T. T.W., PHD. (2016). Gender Dysphoria and the Ethics of Transsexual Surgery." *Ethics and Medicine*.
10. de Vries A.L., Steensma T.D., Doreleijers T.A., Cohen-Kettenis P.T. (2011). Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. *Journal of Sexual Medicine*. 8(8), 2276–2283
11. de Vries AL1, Doreleijers TA, Steensma TD, Cohen-Kettenis PT. (2011). Psychiatric comorbidity in gender dysphoric adolescents. *Journal of Child Psychology and Psychiatry*. 52(11), 1195-1202.
12. Del Pup, L., Mantovani, A., Cavaliere, C., Facchini, G., Luce, A., Sperlongano, P., ... Berretta, M. (2016). Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). *Oncology Reports*. doi:10.3892/or.2016.4886

13. Department of Health and Human Services. (May 2014). National Coverage Determinations 140.3, *Transsexual surgery docket no. a-13-87 decision no. 2576*.
14. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association, 2013. Print.
15. Drummond, K.D., Bradley, S.J., Peterson-Badali, M., Zucker, K.J. (2008). A follow-up study of girls with gender identity disorder. *Developmental Psychology*. 44(1), 34–45.
16. Falletti, Elena (2015), “Judges and Stereotypes on Same-sex Issues: Analysis of Case Law from a Comparative Perspective in English and Italian Family Law,” *Journal of Research in Gender Studies*, 5(2): 147–170.
17. Fuqua, J. S. (March 2013). Treatment and Outcomes of Precocious Puberty: An Update. *The Journal of Clinical Endocrinology & Metabolism*, 98(6), 2198-2207. doi:10.1210/jc.2013-1024.
18. Hembree, Wylie C. "Management of Juvenile Gender Dysphoria." *Current Opinion in Endocrinology & Diabetes and Obesity* 20.6 (2013): 559-64. Web.
19. Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., Spack, N. P., ... Montori, V. M. (September 2009). Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 94(9), 3132-3154. doi:10.1210/jc.2009-0345
20. Hormones and the Body: A Brief Overview. Retrieved from <http://www.ftmguide.org/hormonebasics.html>
21. Kaltiala-Heino, R., Sumia, M., Työlajärvi, M., & Lindberg, N. (2015). Two years of gender identity service for minors: overrepresentation of natal girls with severe problems in adolescent development. *Child and Adolescent Psychiatry and Mental Health*, 9(1). doi:10.1186/s13034-015-0042-y.
22. Kreukels, B. P., & Cohen-Kettenis, P. T. (May 2011). Puberty suppression in gender identity disorder: the Amsterdam experience. *Nature Reviews: Endocrinology*, 7(8), 466-472. doi:10.1038/nrendo.2011.78.
23. Jain, S., Santa-Maria, C., and Gradishar, W.J. (July 2015) "The Role of Ovarian Suppression in Premenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer." *Oncology*, 29.7: 473.



24. Jarin, J., MD, Gomez-Lobo, V., MD. (Spring 2016): "NASPAG Knowledge: Caring for Children and Teens: with Gender Dysphoria." *The North American Society for Pediatric and Adolescent Gynecology*.
25. Lee, J. G., Ylioja, T., & Lackey, M. (2016). Identifying Lesbian, Gay, Bisexual, and Transgender Search Terminology: A Systematic Review of Health Systematic Reviews. *PLOS ONE*, 11(5), e0156210. doi:10.1371/journal.pone.0156210.
26. Liu, J., Jiang, W., Mao, K., An, Y., Su, F., Kim, B., Liu, Q., Jacobs, L. (March 2015) Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. *Springer Science & Business*.
27. MacDonald, T., Noel-Weiss, J., West, D., Walks, M., Biener, M., Kibbe, A., & Myler, E. (2016). Transmasculine individuals' experiences with lactation, chest feeding, and gender identity: a qualitative study. *BMC Pregnancy Childbirth*, 16(1). doi:10.1186/s12884-016-0907-y.
28. March, P., & Schub, T. (2015). Quick Lesson: Gender Identity Disorder in Children. *Cumulative Index to Nursing and Allied Health Literature*.
29. March, P., & Schub, T. (2016). Quick Lesson: Gender Dysphoria. *Cumulative Index to Nursing and Allied Health Literature*.
30. McDonald, Elisabeth. (2015): "Intersex People in Aotearoa New Zealand: The Challenges for Law and Social Policy: Part I: Critiquing Gender Normalizing Surgery." *Victoria University of Wellington Law Review* 46.3 n. pag.
31. Möller B1, Schreier H, Li A, Romer G. (2009). Gender identity disorder in children and adolescents. *Current Problems in Pediatric and Adolescent Health Care*. 39(5), 117-143
32. Mozes, A. (2014). Puberty suppression benefits gender-questioning teens: study. Retrieved from <http://medicalxpress.com/news/2014-09-puberty-suppression-benefits-gender-questioning-teens.html> .
33. Norton, A. (May 2016). Penis Reconstructions 'Life-Altering' for Men, Studies Show: *MedlinePlus*. Retrieved from [https://medlineplus.gov/news/fullstory\\_158725.html](https://medlineplus.gov/news/fullstory_158725.html).
34. Pedersen, D. D. (2014). 105 Gender Identity Disorder. In *Psychnotes: A clinical pocket guide* (4th ed.). F.A. Davis Company.

35. Sjoen, T, G. Baere, E., Heylens, G., Sajevelts, T., Verroken, C., (2014). Mother and daughter became father and son: a case report. *Asian Journal of Andrology*, 0(0), 0. doi:10.4103/1008-682x.145430.
36. Schub, T., & Kornusky, J. (2016). Evidence- Based Care Sheet: Transgenderism. *Cumulative Index to Nursing and Allied Health Literature*.
37. Sharma, A., Aoun, P., Wigham, J., Weist, S., & Veldhuis, J. D. (2013). Gender determines ACTH recovery from hypercortisolemia in healthy older humans. *Metabolism*, 62(12), 1819-1829. doi:10.1016/j.metabol.2013.08.014.
38. Spack, N.P., Edwards-Leeper, L., Feldman, H.A., Leibowitz, S., Mandel, F., Diamond D.A., & Vance S.R. (2012). Children and adolescents with gender identity disorder referred to a pediatric medical center. *Pediatrics*. 129(3), 418-425.
39. Somod, M. E., Vestergaard, E. T., Kristensen, K., & Birkebæk, N. H. (April 2016). Increasing incidence of premature thelarche in the Central Region of Denmark - Challenges in differentiating girls less than 7 years of age with premature thelarche from girls with precocious puberty in real-life practice. *International Journal of Pediatric Endocrinology*, 2016(1). Doi: 10.1186/s13633-016-0022-x.
40. *Smith v. Rasmussen*, 249 F. 3d 755 (8th Cir. 2001).
41. Spielmann, S., Partsch, C. J., Gosch, A., & Pankau, R. (2015). Treatment of central precocious puberty and early puberty with GnRH analog in girls with Williams-Beuren syndrome. *Journal of Pediatric Endocrinology and Metabolism*, 28(11-12). doi:10.1515/jpem-2014-0393.
42. Tack, L. J., Craen, M., Dhondt, K., Vanden Bossche, H., Laridaen, J., & Cools, M. (2016). Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. *Biology of Sex Differences*, 7(1). doi:10.1186/s13293-016-0067-9.
43. U.S. Food and Drug Administration (2015) Highlights of prescribing information: Eligard (Ref. No. 3267004).
44. U.S Food and Drug Administration (2015) Lupron Injection (leuprolide acetate) (ref. no. 3540421).
45. U.S Food and Drug Administration (2015) Highlights of prescribing information: Trelstar (triptorelin pamoate for injectable suspension) (ref. no. 3540716).

46. U.S Food and Drug Administration (2015) Highlights of prescribing information: Supprelin LA (histelin acetate) (ref. no. 3286655).
47. U.S Food and Drug Administration (2015) Synarel (nafarelin acetate) nasal solution (ref. no. 3803448).
48. U.S Food and Drug Administration (2015) Highlights of prescribing information: Vantas (Histrelin acetate) (ref. no. 3287862).
49. U.S Food and Drug Administration (2015) Highlights of prescribing information: Zoladex (goserlin acetate implant) (ref no. 3701753).
50. Vance, S. R., Ehrensaft, D., & Rosenthal, S. M. (2014). Psychological and Medical Care of Gender Nonconforming Youth. *PEDIATRICS*, *134*(6), 1184-1192. doi:10.1542/peds.2014-0772.
51. Vrouenraets, L. J., Fredriks, A. M., Hannema, S. E., Cohen-Kettenis, P. T., & De Vries, M. C. (2015). Early Medical Treatment of Children and Adolescents with Gender Dysphoria: An Empirical Ethical Study. *Journal of Adolescent Health*, *57*(4), 367-373. doi:10.1016/j.jadohealth.2015.04.004.
52. V., Vasundhara, C., Kandasamy, D., & Gupta, N. (2016). Clinical, hormonal and radiological profile of 46XY disorders of sexual development. *Indian Journal of Endocrinology and Metabolism*, *20*(3), 300. doi:10.4103/2230-8210.179999
53. Wadle, L. D. (2015). Controversial medical Treatments for Children: The Roles of Parents and of the State. *American Bar Association Family Law Quarterly*, *49*, No. 3. Retrieved from [http://www.americanbar.org/publications/family\\_law\\_quarterly\\_home/family\\_law\\_quarterly\\_archive/family\\_flq-abstract4903.html](http://www.americanbar.org/publications/family_law_quarterly_home/family_law_quarterly_archive/family_flq-abstract4903.html)
54. Wallien, M.S., Cohen-Kettenis, P.T. (2008). Psychosexual outcome of gender-dysphoric children. *Journal of the American Academy of Child and Adolescent Psychiatry*. *47*(12), 1413 -1423.
55. Wojniusz, S., Callens, N., Sütterlin, S., Andersson, S., De Schepper, J., Gies, I., Haraldsen, I. R. (July 2016). Cognitive, Emotional, and Psychosocial Functioning of Girls Treated with Pharmacological Puberty Blockage for Idiopathic Central Precocious Puberty. *Frontiers in Psychology*, *7*. doi:10.3389/fpsyg.2016.01053.

56. Yan, S., Li, K., Jiao, X., & Zou, H. (2015). Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. *OTT*, 1433. doi:10.2147/ott.s86817.